Mission & Vision
We’re advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Our CEO, Brent Vaughan speaks about the promise of neuromodulation to improve the lives of millions of Alzheimer’s patients.
Our Novel Platform
Introducing our novel platform for neurodegenerative disease
Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease.
Our Pipeline
Leveraging our platform across multiple neurodegenerative diseases.
Focus
CogTx-001
Alzheimer’s Disease
CogTx-002
Mild Cognitive Impairment
CogTx-003
Parkinson's Disease
CogTx-004
TBI-related Dementia
CogTx-005
Ischemic Stroke
CogTx-006
Multiple Sclerosis
Discovery
Preclinical
Early Clinical
Pivotal Clinical
In market
Latest News & Updates
Stay up to date
Aug 3, 2022
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
May 2, 2022
Some health apps are able not just to diagnose diseases, but also to treat them
Apr 13, 2022
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
Mar 31, 2022
With pharma still struggling in Alzheimer’s, health tech companies want a swing
Careers
Join our growing team
Design
Industrial Designer
Cambridge, MA
Regulatory and Compliance
Director of Quality
Remote
Engineering
Signal Processing Scientist/Engineer
Cambridge, MA
Design
User Experience Designer
Remote
Product
Senior Product Manager
Remote
Product
Product Manager
Remote